drugset
drugset / Trial / NCT05522153

Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

NCT05522153 ↗

Phase 1 Completed 61 enrolled Virtua Health, Inc. Becton, Dickinson and Company · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.

Timeline

Start
2021-05-01
Primary completion
2023-06-08
Completion
2023-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Arista Unknown 5 g Other

Indications

No indication recorded.